1
|
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
|
N Engl J Med
|
1998
|
4.93
|
2
|
Sequential sorafenib and sunitinib for renal cell carcinoma.
|
J Urol
|
2009
|
2.12
|
3
|
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.
|
Ann Oncol
|
2010
|
2.11
|
4
|
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
|
Ann Oncol
|
2002
|
2.03
|
5
|
Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
|
Ann Oncol
|
2011
|
2.03
|
6
|
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
|
Ann Oncol
|
2010
|
1.91
|
7
|
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.
|
J Clin Oncol
|
1997
|
1.77
|
8
|
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
|
Ann Oncol
|
2010
|
1.65
|
9
|
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
|
Br J Cancer
|
2013
|
1.65
|
10
|
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
|
J Clin Oncol
|
2000
|
1.59
|
11
|
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
|
Ann Oncol
|
2009
|
1.57
|
12
|
Heat and moisture exchanger vs heated humidifier during long-term mechanical ventilation. A prospective randomized study.
|
Chest
|
1991
|
1.43
|
13
|
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
|
Ann Oncol
|
2007
|
1.35
|
14
|
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
|
Ann Oncol
|
2011
|
1.34
|
15
|
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
|
Eur J Cancer
|
2011
|
1.29
|
16
|
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
|
Br J Cancer
|
2013
|
1.24
|
17
|
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
|
Eur J Cancer
|
2003
|
1.21
|
18
|
Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.
|
Cancer
|
1998
|
1.18
|
19
|
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
|
Ann Oncol
|
2008
|
1.18
|
20
|
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
|
Ann Oncol
|
2009
|
1.15
|
21
|
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
|
Ann Oncol
|
2010
|
1.13
|
22
|
Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.
|
Cancer Res
|
1992
|
1.13
|
23
|
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
|
Br J Cancer
|
2009
|
1.09
|
24
|
Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit.
|
Infect Control Hosp Epidemiol
|
1990
|
1.07
|
25
|
Exosomes for cancer immunotherapy.
|
Ann Oncol
|
2004
|
1.03
|
26
|
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
|
Ann Oncol
|
2009
|
0.98
|
27
|
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.
|
J Clin Oncol
|
1996
|
0.97
|
28
|
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients.
|
Clin Exp Immunol
|
2000
|
0.97
|
29
|
Severity-of-illness scores for neutropenic cancer patients in an intensive care unit: Which is the best predictor? Do multiple assessment times improve the predictive value?
|
Crit Care Med
|
1998
|
0.96
|
30
|
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
|
Br J Cancer
|
2011
|
0.96
|
31
|
Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures.
|
Eur J Cancer
|
1997
|
0.94
|
32
|
The postchemotherapy PSA surge syndrome.
|
Ann Oncol
|
2008
|
0.92
|
33
|
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
|
Br J Cancer
|
2013
|
0.91
|
34
|
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis.
|
Lab Invest
|
1999
|
0.90
|
35
|
Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
|
Oncogene
|
2011
|
0.90
|
36
|
Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas.
|
Blood
|
2000
|
0.89
|
37
|
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
|
Ann Oncol
|
2013
|
0.88
|
38
|
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.
|
Gene Ther
|
2003
|
0.88
|
39
|
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
|
J Clin Oncol
|
1998
|
0.88
|
40
|
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
|
Br J Cancer
|
2012
|
0.87
|
41
|
In situ demonstration of renal-cell-carcinoma-specific T-cell clones.
|
Int J Cancer
|
1996
|
0.87
|
42
|
[CCAFU Recommendations 2013: Renal cancer].
|
Prog Urol
|
2013
|
0.87
|
43
|
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
|
Ann Oncol
|
2002
|
0.87
|
44
|
[Eruptive nevi associated with sorafenib treatment].
|
Ann Dermatol Venereol
|
2008
|
0.86
|
45
|
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo.
|
Int J Cancer
|
1995
|
0.86
|
46
|
Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
|
Cancer J Sci Am
|
2000
|
0.85
|
47
|
Early tracheotomy in neutropenic, mechanically ventilated patients: rationale and results of a pilot study.
|
Support Care Cancer
|
1995
|
0.85
|
48
|
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
|
Ann Oncol
|
2013
|
0.85
|
49
|
Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy.
|
Biochem Pharmacol
|
1999
|
0.85
|
50
|
The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration.
|
Int J Cancer
|
1994
|
0.84
|
51
|
In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
|
Cancer Res
|
1995
|
0.84
|
52
|
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
|
Ann Oncol
|
2010
|
0.83
|
53
|
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
|
J Am Coll Surg
|
1995
|
0.82
|
54
|
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
|
Br J Cancer
|
2013
|
0.81
|
55
|
Esophageal squamous cell carcinoma: the specific limited place of surgery defined by a prospective multivariate study of prognostic factors after surgical approach.
|
Eur J Surg Oncol
|
1992
|
0.81
|
56
|
[Recommendations Onco-Urology 2010: Kidney cancer].
|
Prog Urol
|
2010
|
0.81
|
57
|
5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure?
|
Eur J Cancer
|
1996
|
0.80
|
58
|
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
|
Ann Oncol
|
2009
|
0.80
|
59
|
Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
|
J Biol Response Mod
|
1990
|
0.80
|
60
|
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
|
Ann Oncol
|
2000
|
0.80
|
61
|
Should the number of pulmonary metastases influence the surgical decision?
|
Eur J Cardiothorac Surg
|
1997
|
0.80
|
62
|
Safety of tracheotomy in neutropenic patients: a retrospective study of 26 consecutive cases.
|
Intensive Care Med
|
1995
|
0.80
|
63
|
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
|
Cancer
|
1999
|
0.80
|
64
|
Wegener's granulomatosis presenting as diffuse pulmonary hemorrhage.
|
Intensive Care Med
|
1991
|
0.80
|
65
|
Acute myocardiotoxicity during 5-fluorouracil therapy.
|
Intensive Care Med
|
1990
|
0.79
|
66
|
The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.
|
Eur Cytokine Netw
|
2005
|
0.79
|
67
|
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma.
|
Int J Cancer
|
1993
|
0.79
|
68
|
Recombinant interferon-alpha efficacy in relapsed adult nephroblastoma: a case report.
|
J Urol
|
1994
|
0.79
|
69
|
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology.
|
Eur J Cancer
|
2012
|
0.79
|
70
|
Overrepresentation of 7q31 and 17q in renal cell carcinomas.
|
Genes Chromosomes Cancer
|
1998
|
0.78
|
71
|
[Epidermoid cancer of the esophagus: is the combination of chemotherapy then surgery beneficial?].
|
Bull Cancer
|
1989
|
0.78
|
72
|
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
|
J Immunother
|
1999
|
0.78
|
73
|
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
|
J Immunother
|
2000
|
0.78
|
74
|
T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapy.
|
J Immunother Emphasis Tumor Immunol
|
1994
|
0.78
|
75
|
Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients.
|
Int J Cancer
|
1993
|
0.77
|
76
|
Novel and bone-targeted agents for CRPC.
|
Ann Oncol
|
2012
|
0.77
|
77
|
T-cell receptor repertoire in neuroblastoma patients.
|
Cancer Res
|
1996
|
0.77
|
78
|
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial.
|
Eur Cytokine Netw
|
2001
|
0.77
|
79
|
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
|
Med Oncol
|
2009
|
0.77
|
80
|
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
|
Ann Oncol
|
2015
|
0.76
|
81
|
T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines.
|
Int J Cancer
|
1997
|
0.76
|
82
|
[What may be the waiting time between the diagnosis and surgical treatment of kidney cancer?].
|
Prog Urol
|
2008
|
0.75
|
83
|
Blood gas analysis in patients with hyperleucocytosis: validity of repeated measures on same sampling without ice?
|
Leuk Res
|
1994
|
0.75
|
84
|
Lithium concentrations during cisplatin-based chemotherapy: evidence for renal interaction.
|
Cancer Chemother Pharmacol
|
1995
|
0.75
|
85
|
Do bacteriuria and candiduria have predictive value in the diagnosis of postlaparotomy peritonitis?
|
Clin Infect Dis
|
1994
|
0.75
|
86
|
Thrombotic microangiopathy associated with Streptococcus pneumoniae infection: role of renal biopsy.
|
Clin Infect Dis
|
1995
|
0.75
|
87
|
[The place of laparoscopic nephrectomy in the elderly subject].
|
Prog Urol
|
2009
|
0.75
|
88
|
[Atypical cysts and cystic tumours of the kidney: histological, radiological and surgical considerations. Conclusions of the AFU 2007 forum].
|
Prog Urol
|
2008
|
0.75
|
89
|
Cellular and molecular immunology of an important regulatory cytokine. New York 9-12, November 1995.
|
Eur Cytokine Netw
|
1996
|
0.75
|
90
|
[Bullous dermatosis with linear IgA deposits along the basement membrane during treatment with gamma interferon and interleukin-2].
|
Ann Dermatol Venereol
|
1990
|
0.75
|
91
|
[Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management].
|
Presse Med
|
1986
|
0.75
|
92
|
[Anastomotic fistula after gastrectomy. Diagnostic value of radiologic monitoring. Retrospective study of 123 gastrectomies].
|
Presse Med
|
1987
|
0.75
|
93
|
Studies on NK cell purification by negative selection in human peripheral blood.
|
Biotherapy
|
1992
|
0.75
|
94
|
[A rare cause of digital arteritis with Raynaud's phenomenon and digital necrosis: virus B hepatitis. 3 cases].
|
Ann Med Interne (Paris)
|
1982
|
0.75
|
95
|
Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors.
|
Ann Oncol
|
2011
|
0.75
|
96
|
[Leg aneurysm complicating bacterial endocarditis. 2 cases].
|
Presse Med
|
1983
|
0.75
|
97
|
"Spontaneous" regressions of a metastatic adenocarcinoma transmitted by a cadaver kidney graft: support for immunotherapy?
|
Cancer Immunol Immunother
|
1994
|
0.75
|
98
|
[Reliability of the response rate in oncology: analysis of the causes for variation].
|
Bull Cancer
|
2000
|
0.75
|
99
|
[Targeted therapies: sequential and combined treatments].
|
Bull Cancer
|
2010
|
0.75
|
100
|
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring.
|
Int J Cancer
|
1994
|
0.75
|
101
|
[Cardiotoxicity of 5-fluorouracil. Apropos of a new case].
|
Arch Mal Coeur Vaiss
|
1985
|
0.75
|
102
|
Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.
|
Support Care Cancer
|
1994
|
0.75
|
103
|
[Pseudoparalysis induced by cancer chemotherapy (cis-platinum)].
|
Cah Anesthesiol
|
1985
|
0.75
|
104
|
[A multivariate prospective study of prognostic factors in 200 operated epidermoid cancers of the esophagus. Definition of patients for whom surgical resection was of benefit].
|
Gastroenterol Clin Biol
|
1993
|
0.75
|
105
|
Thalidomide and venous thrombosis.
|
Ann Intern Med
|
2002
|
0.75
|
106
|
[Update on the different histological types of renal cell carcinoma and their specific treatment].
|
Prog Urol
|
2011
|
0.75
|
107
|
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.
|
J Immunother Emphasis Tumor Immunol
|
1995
|
0.75
|
108
|
[Renal tolerability of cisplatin].
|
Rev Med Interne
|
1996
|
0.75
|
109
|
[Case report of kidney cancer from JOUM 2010].
|
Prog Urol
|
2011
|
0.75
|
110
|
[Do ablative treatments modify the management of kidney tumors in the elderly?].
|
Prog Urol
|
2009
|
0.75
|
111
|
[Tracheal rupture during intubation for general anesthesia].
|
Ann Fr Anesth Reanim
|
1986
|
0.75
|
112
|
[Anatomo-clinical conference at the Pitié-Salpêtrière. Polyarthritis, renal insufficiency and arterial hypertension in a 47-year-old woman].
|
Ann Med Interne (Paris)
|
1982
|
0.75
|
113
|
Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure.
|
Am Heart J
|
1985
|
0.75
|
114
|
Contribution to the study of unconscious psychic mechanism in the anesthesiologist.
|
Acta Anaesthesiol Belg
|
1984
|
0.75
|
115
|
[Long-term clinical and hemodynamic results of the treatment of refractory cardiac failure with molsidomine].
|
Arch Mal Coeur Vaiss
|
1984
|
0.75
|
116
|
[Current role of lymph node dissection in renal cell carcinoma: review of the literature by the Oncology Committee of the French Association of Urology (CCAFU)].
|
Prog Urol
|
2012
|
0.75
|
117
|
[Cytokines and solid tumors].
|
Rev Prat
|
1993
|
0.75
|
118
|
In vivo activation of LAK cells during systemic IL-2 therapy.
|
Eur Cytokine Netw
|
1991
|
0.75
|
119
|
[Cancer of the kidney in the adult].
|
Bull Cancer
|
1998
|
0.75
|
120
|
[Kidney cancer management in 2007: news and recommendations].
|
Prog Urol
|
2008
|
0.75
|
121
|
[Treatment of metastatic malignant insulinomas. 2 cases].
|
Presse Med
|
1995
|
0.75
|
122
|
[Clamping modalities during partial nephrectomy: technical aspects and functional consequences. Review by the Comité de cancérologie de l'Association française d'urologie (CCAFU)].
|
Prog Urol
|
2009
|
0.75
|
123
|
[Spontaneous bilateral chylothorax. Cure by a single puncture].
|
Presse Med
|
1983
|
0.75
|
124
|
Cerebral vasculitis after interleukin-2 therapy for renal cell carcinoma.
|
J Immunother Emphasis Tumor Immunol
|
1995
|
0.75
|
125
|
[Renal cell carcinoma management and therapies in 2010].
|
Bull Cancer
|
2010
|
0.75
|
126
|
[Cancer immunotherapy: immunologic bases, reality and hopes].
|
Bull Cancer
|
1993
|
0.75
|
127
|
FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.
|
Ann Oncol
|
2010
|
0.75
|
128
|
[New drugs in metastatic castration-resistant prostate cancer].
|
Bull Cancer
|
2010
|
0.75
|
129
|
[How to prevent the tumor lysis syndrome].
|
Presse Med
|
1985
|
0.75
|
130
|
[Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer].
|
Prog Urol
|
2010
|
0.75
|
131
|
Adjuvant treatment with IL-2 or interferon-alpha in renal cell carcinoma: a French multicentric study.
|
Cancer Biother Radiopharm
|
1996
|
0.75
|
132
|
[Therapeutic strategy in metastatic renal cancer].
|
Rev Prat
|
1992
|
0.75
|
133
|
[Hyperuricemia resistant to urate oxidase. Efficacy of high doses].
|
Presse Med
|
1984
|
0.75
|